Zepbound Approved for Chronic Weight Management and obesity treatment:

The U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with at least one weight-related condition (e.g., high blood pressure, type 2 diabetes, or high cholesterol).

Zepbound injection works by mimicking two hormones that regulate appetite and food intake: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), and it's a once-weekly injectable medication.

In two clinical trials, Zepbound was shown to be effective in helping people lose weight and keep it off.

In the larger of the two trials, people who received Zepbound lost an average of 18% of their body weight over 72 weeks, compared to an average of 5% weight loss in the placebo group.

Safety precautions of the Zepbound injection:

Zepbound should not be used in people with a personal or family history of medullary thyroid cancer, people with Multiple Endocrine Neoplasia syndrome type 2, or people with a history of pancreatitis or severe gastrointestinal disease.

Zepbound should also not be used in combination with other GLP-1 receptor agonists.

The most common side effects of Zepbound are diarrhea, nausea, vomiting, abdominal pain, constipation, injection site reactions, hypersensitivity reactions, fatigue, burping, gastroesophageal reflux disease and hair loss.